Dr. Shune is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2330 Shawnee Mission Pkwy
Ste 210
Westwood, KS 66205Phone+1 913-588-6030Fax+1 913-588-4085
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2010 - 2013- University of MinnesotaResidency, Internal Medicine, 2007 - 2010
Istanbul University FomClass of 2004
Certifications & Licensure
KS State Medical License 2014 - 2025
MO State Medical License 2021 - 2025
Clinical Trials
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients Start of enrollment: 2021 Nov 02
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 51 citationsSocioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access.Nausheen Ahmed, Moazzam Shahzad, Ernie Shippey, Rajat Bansal, Muhammad Umair Mushtaq
Transplantation and Cellular Therapy. 2022-07-01 - 13 citationsSafety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.Danai Dima, James A Davis, Nausheen Ahmed, Xuefei Jia, Aishwarya Sannareddy
Transplantation and Cellular Therapy. 2024-03-01 - 5 citationsCarfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).Dante Pennipede, Ghulam Rehman Mohyuddin, Ryan Hawkins, Siddhartha Ganguly, Leyla Shune
European Journal of Haematology. 2021-08-31
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
